﻿<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
  <channel>
    <title>Aidsmap news - English</title>
    <description> </description>
    <link>http://www.aidsmap.com/Aidsmap-news-English/page/1260794/</link>
    <language>en-gb</language>
    <copyright>NAM Publications - 2012</copyright>
    <pubDate>Fri, 10 Feb 2012 18:20:48 GMT</pubDate>
    <lastBuildDate>Fri, 10 Feb 2012 18:20:48 GMT</lastBuildDate>
    <docs>http://backend.userland.com/rss</docs>
    <generator>RSS.NET: http://www.rssdotnet.com/</generator>
    <item>
      <title>Cotrimoxazole prophylaxis reduces death rate by almost 60% in adults taking ART in low and middle-income countries</title>
      <description>Cotrimoxazole significantly
reduces death among adults on ART in low and middle-income countries, according to a systematic review and
meta-analysis published in the October online edition of the Bulletin of the World Health Organization.
Pooled analysis of seven
studies showed that cotrimoxazole prophylaxis reduced the incidence of death by
close to 60% (0.42, 95% CI:</description>
      <link>http://www.aidsmap.com/page/2243024/</link>
      <category>Access to medicines and treatment</category>
      <category>Opportunistic infections</category>
      <category>Sub-Saharan Africa</category>
      <author>Carole Leach-Lemens</author>
      <guid isPermaLink="True">http://www.aidsmap.com/page/2243024/</guid>
      <pubDate>Fri, 10 Feb 2012 12:00:00 GMT</pubDate>
    </item>
    <item>
      <title>Cotrimoxazole prophylaxis is cost-effective for people starting ART in sub-Saharan Africa</title>
      <description>Achieving full coverage of
cotrimoxazole prophylaxis during the first six months of antiretroviral therapy
would be a highly cost-effective way of reducing early death among those with
advanced HIV infection in sub-Saharan Africa, researchers report in the advance
online edition of the Journal of Acquired
Immune Deficiency Syndromes.
The researchers developed a
decision-analytic model from a health</description>
      <link>http://www.aidsmap.com/page/2243061/</link>
      <category>Delivery of care</category>
      <category>Opportunistic infections</category>
      <category>Starting treatment</category>
      <category>Sub-Saharan Africa</category>
      <author>Carole Leach-Lemens</author>
      <guid isPermaLink="True">http://www.aidsmap.com/page/2243061/</guid>
      <pubDate>Fri, 10 Feb 2012 11:50:00 GMT</pubDate>
    </item>
    <item>
      <title>Use of some anti-HIV drugs during pregnancy linked to cleft lip and palate; investigators urge cautious interpretation of results</title>
      <description>US investigators have identified a possible
association between the use of antiretroviral therapy during pregnancy and an
increased risk of having a baby with a cleft lip or palate. The study,
published in the January edition of Cleft
Palate-Craniofacial Journal, found preliminary evidence seven anti-HIV
drugs may increase the risk of this birth abnormality.
However, the</description>
      <link>http://www.aidsmap.com/Use-of-some-anti-HIV-drugs-during-pregnancy-linked-to-cleft-lip-and-palate-investigators-urge-cautious-interpretation-of-results/page/2232917/</link>
      <category>Prevention of mother-to-child transmission</category>
      <category>United States</category>
      <author>Michael Carter</author>
      <guid isPermaLink="True">http://www.aidsmap.com/Use-of-some-anti-HIV-drugs-during-pregnancy-linked-to-cleft-lip-and-palate-investigators-urge-cautious-interpretation-of-results/page/2232917/</guid>
      <pubDate>Thu, 09 Feb 2012 15:10:00 GMT</pubDate>
    </item>
    <item>
      <title>Increased risk of anal cancer for all groups with HIV </title>
      <description>Gay men are not the
only group of HIV-positive patients who have an increased risk of anal cancer,
according to North American research published in the online edition of Clinical Infectious Diseases. The
researchers found that incidence of the cancer was also significantly higher in
non-gay HIV-positive men as well as HIV-positive women when</description>
      <link>http://www.aidsmap.com/Increased-risk-of-anal-cancer-for-all-groups-with-HIV/page/2234922/</link>
      <category>Canada</category>
      <category>Cancer</category>
      <category>Men who have sex with men (MSM)</category>
      <category>United States</category>
      <category>Women</category>
      <author>Michael Carter</author>
      <guid isPermaLink="True">http://www.aidsmap.com/Increased-risk-of-anal-cancer-for-all-groups-with-HIV/page/2234922/</guid>
      <pubDate>Wed, 08 Feb 2012 10:10:00 GMT</pubDate>
    </item>
    <item>
      <title>Professional tattooing in sterile environment not associated with risk of hepatitis C</title>
      <description>Tattooing or body
piercing in professional parlours is not associated with an increased risk of
infection with hepatitis C virus, a literature review published in the online
edition of Clinical Infectious Diseases
shows. However, the authors did find evidence that tattooing in non-sterile
environments, such as prisons, was associated with the infection. They also
found isolated</description>
      <link>http://www.aidsmap.com/Professional-tattooing-in-sterile-environment-not-associated-with-risk-of-hepatitis-C/page/2234340/</link>
      <category>Hepatitis C transmission and prevention</category>
      <category>Injecting drug use</category>
      <author>Michael Carter</author>
      <guid isPermaLink="True">http://www.aidsmap.com/Professional-tattooing-in-sterile-environment-not-associated-with-risk-of-hepatitis-C/page/2234340/</guid>
      <pubDate>Wed, 08 Feb 2012 06:30:00 GMT</pubDate>
    </item>
    <item>
      <title>New BHIVA guidelines recommend discussion with all patients on potential of HIV treatment to protect sexual partners</title>
      <description>The British HIV Association (BHIVA) today recommends that doctors
should discuss the evidence for the effectiveness of antiretroviral treatment as
prevention with all patients with HIV, and that it should be offered those who
want to protect their partners from the risk of HIV infection – even if they
have no immediate clinical need</description>
      <link>http://www.aidsmap.com/New-BHIVA-guidelines-recommend-discussion-with-all-patients-on-potential-of-HIV-treatment-to-protect-sexual-partners/page/2235411/</link>
      <category>Infectiousness and treatment as prevention</category>
      <category>Must see</category>
      <category>Starting treatment</category>
      <category>Treatment guidelines</category>
      <category>United Kingdom</category>
      <author>Keith Alcorn</author>
      <guid isPermaLink="True">http://www.aidsmap.com/New-BHIVA-guidelines-recommend-discussion-with-all-patients-on-potential-of-HIV-treatment-to-protect-sexual-partners/page/2235411/</guid>
      <pubDate>Mon, 06 Feb 2012 19:50:00 GMT</pubDate>
    </item>
    <item>
      <title>US CDC recommends HPV vaccine for young men</title>
      <description>Young men and adolescent boys between the ages of 11 and 21
should be vaccinated against human papillomavirus, the cause of genital warts,
anal and cervical cancer, the Advisory Committee on Immunization Practices has
recommended, in a new Adult Immunization Schedule published in Annals of Internal Medicine.
The committee also recommends that all gay</description>
      <link>http://www.aidsmap.com/US-CDC-recommends-HPV-vaccine-for-young-men/page/2235492/</link>
      <category>Immunisations</category>
      <category>Sexually transmitted infections</category>
      <category>Vaccines</category>
      <author>Keith Alcorn</author>
      <guid isPermaLink="True">http://www.aidsmap.com/US-CDC-recommends-HPV-vaccine-for-young-men/page/2235492/</guid>
      <pubDate>Mon, 06 Feb 2012 08:50:00 GMT</pubDate>
    </item>
    <item>
      <title>Gardasil protects against recurrence of pre-cancerous anal lesions in HIV-negative gay men</title>
      <description>The genital wart
vaccine Gardasil significantly
reduces the risk of high-grade pre-cancerous anal lesion recurrence in men who
have sex with men, US investigators report in the online edition of Clinical Infectious Diseases.
The vaccine reduced
the risk of lesion recurrence by approximately 50% in the first two years after
immunisation. There was some evidence that</description>
      <link>http://www.aidsmap.com/Gardasil-protects-against-recurrence-of-pre-cancerous-anal-lesions-in-HIV-negative-gay-men/page/2234343/</link>
      <category>Men who have sex with men (MSM)</category>
      <category>Sexually transmitted infections</category>
      <category>United States</category>
      <author>Michael Carter</author>
      <guid isPermaLink="True">http://www.aidsmap.com/Gardasil-protects-against-recurrence-of-pre-cancerous-anal-lesions-in-HIV-negative-gay-men/page/2234343/</guid>
      <pubDate>Mon, 06 Feb 2012 08:30:00 GMT</pubDate>
    </item>
    <item>
      <title>For patients with HIV viral load is key in immune response to yellow fever vaccine</title>
      <description>Viral load is the only factor associated
with a poorer antibody response to the yellow fever vaccine in patients with
HIV, according to a French study published in the online edition of the Journal of Acquired Immune Deficiency
Syndromes.
For patients vaccinated after diagnosis
with HIV, an undetectable viral load was the “unique determinant” of</description>
      <link>http://www.aidsmap.com/For-patients-with-HIV-viral-load-is-key-in-immune-response-to-yellow-fever-vaccine/page/2229704/</link>
      <category>Health problems</category>
      <category>Immunisations</category>
      <category>Latin America</category>
      <category>Must see</category>
      <category>Sub-Saharan Africa</category>
      <category>Travel</category>
      <category>Western and Central Europe</category>
      <author>Michael Carter</author>
      <guid isPermaLink="True">http://www.aidsmap.com/For-patients-with-HIV-viral-load-is-key-in-immune-response-to-yellow-fever-vaccine/page/2229704/</guid>
      <pubDate>Thu, 02 Feb 2012 08:10:00 GMT</pubDate>
    </item>
    <item>
      <title>Contraception in HIV prevention trials: injectable hormonal methods more effective?</title>
      <description>Women
using injectable (hormonal) contraceptives had a significantly lower rate of
pregnancy compared to those using oral contraception in a major HIV prevention study, researchers report in the advance online edition of AIDS.
However, the same study also found that women who used an injectable hormonal contraceptive method were at higher risk of</description>
      <link>http://www.aidsmap.com/Contraception-in-HIV-prevention-trials-injectable-hormonal-methods-more-effective/page/2229312/</link>
      <category>Conception</category>
      <category>Contraception</category>
      <category>Sub-Saharan Africa</category>
      <author>Carole Leach-Lemens</author>
      <guid isPermaLink="True">http://www.aidsmap.com/Contraception-in-HIV-prevention-trials-injectable-hormonal-methods-more-effective/page/2229312/</guid>
      <pubDate>Thu, 02 Feb 2012 07:10:00 GMT</pubDate>
    </item>
  </channel>
</rss>
